Fruit‐Derived Extracellular Vesicles Engineered Structural Droplet Drugs for Enhanced Glioblastoma Chemotherapy

Jianping Chen,Jiahao Pan,Sijia Liu,Yangning Zhang,Suinan Sha,Haoyan Guo,Xuejiao Wang,Xiangrong Hao,Houwang Zhou,Sijian Tao,Ying Wang,Jun‐Bing Fan

DOI: https://doi.org/10.1002/adma.202304187

IF: 29.4

2023-08-19

Advanced Materials

Abstract:Existing solid nanoparticle‐based drug delivery systems remain a great challenge for glioblastoma chemotherapy due to their poor capacities in crossing the blood‐brain barrier/blood‐brain tumor barrier (BBB/BBTB). Herein, we demonstrated fruit‐derived extracellular vesicles (EVs)‐engineered structural droplet drugs (ESDD) by programming the self‐assembly of fruit‐derived EVs at the DOX@squalene‐PBS interface, greatly enhancing the antitumor efficacy against glioblastoma. The EVs‐engineered structural droplet drugs experience a flexible delivery via deformation‐amplified macropinocytosis and membrane fusion, enabling them to highly efficiently cross BBB/BBTB and deeply penetrate glioblastoma tissues. As expected, the EVs‐engineered structural droplet drugs exhibited 2.5‐fold intracellular uptake, 2.2‐fold transcytosis, and 5‐fold membrane fusion as higher as the EVs (cRGD modified), allowing the highly efficient accumulation, deep penetration, and cellular internalization into the glioblastoma tissues and thereby significantly extending the survival time of glioblastoma mice. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper aims to address the issue of low drug delivery efficiency in glioblastoma chemotherapy caused by the blood-brain barrier (BBB) and the blood-brain tumor barrier (BBTB). Specifically, existing drug delivery systems based on solid nanoparticles exhibit poor capability in crossing these barriers, limiting their therapeutic effectiveness. Therefore, the research team proposed a novel approach by programming fruit-derived extracellular vesicles (EVs) to self-assemble at the DOX@squalene-PBS interface to construct engineered structured drug delivery (ESDD), significantly enhancing the anti-glioblastoma efficacy. This design not only improves drug delivery efficiency but also enhances its ability to penetrate tumor tissues and extends survival time in mouse models. Experimental results show that compared to traditional methods, this new drug delivery system can better traverse the BBB/BBTB and deeply penetrate glioblastoma tissues.